Your medical cannabis journey simplified: find partnered dispensaries, explore pricing options, earn rewards, and get answers to FAQs, all in one spot.
July 18, 2023 12:00 pm ETEstimated Read Time: 5 Minutes
In a bold and unprecedented move, U.S. lawmakers from across the political spectrum have united behind an initiative that could transform mental health care for military personnel. The recently proposed bipartisan bill pledges $75 million towards research into the therapeutic potential of psychedelic substances in treating post-traumatic stress disorder (PTSD).
With this step, the U.S. stands on the cusp of a paradigm shift, challenging existing mental health approaches and potentially ushering in a new era of comprehensive care for our veterans. This article will delve into this historic legislation’s potential benefits and implications.
The Grant Program Details
The heart of this landmark legislation lies in the development of a robust grant program. This initiative aims to promote vital research into the therapeutic potential of four key psychedelic substances—psilocybin, ibogaine, MDMA, and 5-MeO-DMT. These compounds, which have been gaining significant attention in scientific circles for their potential mental health applications, will be the focal point of the funded research.
In addition to funding research, the legislation also earmarks grants for a critical aspect of mental health care delivery—the training of practitioners. Recognizing that the efficacy of treatment relies not only on the therapeutic substances themselves but also on the skill and knowledge of the individuals administering them, this bill explicitly supports the training of practitioners.
This could foster a pool of experts well-versed in applying psychedelic-assisted therapy. This resource could prove invaluable in extending this potentially revolutionary treatment approach to members of the armed forces battling these challenging conditions.
Funding and Eligibility
The program’s funding structure ensures a sustained commitment to the cause, with the Defense Department set to be appropriated $15 million each year from fiscal years 2024 to 2028. This guarantees a total of $75 million for the program’s lifetime, ensuring the continuity and stability needed for the extensive research and training activities underway. In terms of eligibility, the bill extends its reach beyond government institutions, including federal and state agencies.
It also incorporates academic institutions and non-profit organizations, acknowledging the diverse range of entities capable of contributing to this cutting-edge research and training. This inclusive approach fosters a broad-based cooperative effort to achieve the best possible outcomes for active-duty military service members.
See If You Qualify For Medical Marijuana -Select Your State!
Clinical Trials and Reporting
The bill breaks new ground by allowing clinical trials to take place regardless of whether the tested substances fall under federal or military statutes. This opens up unprecedented possibilities for conducting research without the typical constraints imposed by substance classifications. In terms of oversight, the bill institutes a comprehensive reporting system to maintain transparency and track progress.
The Defense Secretary is required to submit a report to Congress every 180 days following the enactment of the legislation. These reports will detail the clinics selected for the grants, the number of service members participating in the clinical trials, and most importantly, any findings or breakthroughs from the trials. This will ensure that lawmakers stay informed about the program’s developments and can respond accordingly as new data emerges.
Support for and Opposition to the Bill
The bill has attracted diverse cosponsors, a testament to its bipartisan appeal. Supporters range from Rep. Lou Correa (D-CA), Alexandria Ocasio-Cortez (D-NY), and Ro Khanna (D-CA) on the Democratic side to Reps. Nancy Mace (R-SC), Matt Gaetz (R-FL), and Jack Bergman (R-MI) representing the Republican party.
Outside of Congress, the bill is being championed by organizations such as Veterans Exploring Treatment Solutions (VETS), with CFO Henry Berkowitz underscoring the urgent need for more research into psychedelic-assisted therapy for active duty service personnel and veterans.
As Berkowitz pointed out, “We have seen real-world evidence which supports the promise of these therapies for hundreds of veterans in our program, but more science is desperately needed,” he said. “We race against a cruel and unrelenting clock as approximately 20 veterans per day —with evidence suggesting it could be twice as many—are lost to suicide on U.S. soil.”
The path to passing this legislation hasn’t been smooth despite the backing. Previous attempts, including an amendment to the National Defense Authorization Act (NDAA), have been blocked or excluded, highlighting the potential challenges that lie ahead for this pioneering bill.
Federal Prohibition and Psychedelics Research
The relationship between federal prohibition and the study of psychedelic substances has been a point of ongoing debate. Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) have been vocal in their stance that the federal prohibition of these substances has hindered necessary research.
They argue that outdated legal restrictions are blocking the exploration of the potential mental health benefits of these substances. The intersection of law and science in this space highlights the importance of legislative reform to unlock the potential of psychedelics as therapeutic agents.
Future Directions and Legislative Actions
Looking forward, several legislative actions promise to further enhance the scope of psychedelic research. These bills, if passed, could expedite the path of psychedelics from research labs to clinical settings. Furthermore, the re-launch of a congressional caucus focused on promoting research into the therapeutic potential of psychoactive substances signals a growing recognition within the legislative body for the importance of this type of study. Together, these efforts mark a promising shift towards a more science-driven approach to policy-making in mental health treatment.
Lemetria Whitehurst is a cannabis nurse educator and writer specializing in cannabis science and culture. Her career in the medical industry spans more than two decades where she began her career as a pharmacy technician before becoming a registered nurse. As an avid reader
and researcher, she is passionate about educating others about cannabis’ medicinal properties.
Cannabis tinctures are relatively new on the scene compared to the long, thousands-year-old history of the cannabis plant itself. It was first recognized for its medicinal use in European medicine in 1839, and by 1851, medicinal cannabis tinctures had made their way into a drug almanac known as the United States Pharmacopeia. Despite prohibition throughout…
Mental health is crucial to our well-being. The National Institute of Mental Health (NIMH) estimates that more than one in five U.S. adults is currently living with a mental health condition. The effort to destigmatize the conversations around mental health is recognized from Mental Health Awareness Month in May to World Suicide Prevention Day in…
Cannabis access has expanded significantly in recent decades. Many states with medical programs have recently adopted recreational legislation allowing anyone 21 years and older to access the plant. This expanded access may leave you wondering if you should bother getting a medical card when you can just purchase cannabis from a recreational store. Medical and…
As cannabis use and accessibility grow nationwide, many universities have established pathways to study the business and science of the plant. Students can research cannabis and its many compounds, pharmacology, cultivation, business, marketing, public policy, and so much more. Beyond cannabis-specific schools like Oaksterdam University and THC University, aspiring cannabis professionals have many options to…
When Piper Lindeen’s son Zach began showing medical issues at just three years old, no one suspected a rare, severe form of epilepsy. Doctors initially didn’t recognize his symptoms as seizures. Eventually, they diagnosed Zach with epilepsy—but by then, his condition had worsened from a few seizures a week to several each day. As it…
The statements made regarding cannabis products on this website have not been evaluated by the Food and Drug Administration (FDA). Cannabis is not an FDA-approved substance and is still illegal under federal law. The information provided on this website is intended for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It is not intended as medical advice and should not be considered as a substitute for advice from a healthcare professional. We strongly recommend that you consult with a physician or other qualified healthcare provider before using any cannabis products. The use of any information provided on this website is solely at your own risk.